期刊文献+

地特胰岛素、甘精胰岛素与中性鱼精蛋白锌胰岛素联合短效胰岛素治疗2型糖尿病的疗效观察 被引量:16

Therapeutic efficacy comparison among insulin detemir, insulin glargine and neutral protamine insulin combined with short-acting insulin premeals injection in treating type 2 diabetes
原文传递
导出
摘要 目的探讨地特胰岛素、甘精胰岛素与中性鱼精蛋白锌胰岛素联合短效胰岛素对2型糖尿病患者的疗效。方法 90例2型糖尿病患者分别应用地特胰岛素、甘精胰岛素与中性鱼精蛋白锌胰岛素联合短效胰岛素治疗,比较3组治疗前后空腹血糖、餐后2h血糖、胰岛素用量及低血糖发生率。结果 3组血糖均下降,但地特胰岛素组降糖效果更明显,且低血糖发生率低。结论与甘精胰岛素、中性鱼精蛋白锌胰岛素相比,地特胰岛素治疗新诊断的2型糖尿病疗效更好,低血糖发生率较低。 Objective To compare of therapeutic efficacy among insulin detemir, insulin glargine and neutral protamine insulin combined with premeals short-acting insulin in type 2 diabetes patients. Methods 90 patients in three groups with type 2 diabetes underwent insulin detemir versus insulin glargine and versus neutral protamine insulin combined with prandial short-acting insulin. We compared fasting blood glucose, postprandial glucose, insulin dosage and the incidence of hypoglycemia between groups before versus after treatment. Results The levels of blood glucose were decreased in three groups, with more efficacy and less hypoglycemia in insulin detemir versus other two groups. Conclusions Compared with insulin glargine group and neutral protamine insulin group, insulin detemir group has better efficacy and lower incidence of low blood glucose in type 2 diabetic patients.
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2011年第7期516-518,共3页 Chinese Journal of Diabetes
关键词 糖尿病 2型 地特胰岛素 甘精胰岛素 中性鱼精蛋白锌胰岛素 Diabetes mellitus, type 2 Insulin detemir Insulin glargine Neutral protamine hagedorn insulin
  • 相关文献

参考文献9

  • 1Gordon J,Pockett RD,Tetlow AP,et al.A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin:an observational database study.Int J Clin Pract,2010,64:1609-1618.
  • 2Dailey G,Admane K,Mercier F,et al.Relationship of insulin dose,A1c lowering,and weight in type 2 diabetes:comparing insulin glargine and insulin detemir.Diabetes Technol Ther,2010,12:1019-1027.
  • 3Morrow L,Hompesch M,Guthrie H,et al.Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.Diabetes Obes Metab,2011,13:75-80.
  • 4Pollock RF,Erny-Albrecht KM,Kalsekar A,et al.Long-acting insulin analogs:a review of "real-world" effectiveness in patients with type 2 diabetes.Curr Diabetes Rev,2011,7:61-74.
  • 5Retnakaran R,Qi Y,Opsteen C,et al.Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications:a pilot study with sitagliptin.Diabetes Obes Metab,2010,12:909-915.
  • 6Kato T,Tokubuchi I,Muraishi K,et al.Distinct pharmacodynamics of insulin glargine and insulin detemir:crossover comparison in type 1 and type 2 diabetic patients on basal-bolus regimen.Diabetes Res Clin Pract,2010,90:e64-e66.
  • 7Vigneri R,Squatrito S,Sciacca L.Insulin and its analogs:actions via insulin and IGF receptors.Acta Diabetol,2010,47:271-278.
  • 8Valentine WJ,Aagren M,Haglund M,et al.Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden.Scand J Public Health,2011,39:79-87.
  • 9Fujii H,Watanabe Y,Ueki A,et al.An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes.Int J Clin Pract,2010,64:1512-1519.

同被引文献140

引证文献16

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部